Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [2608]

AACR 2015: Adding a dual mTOR inhibitor to chemo may benefit some ovarian and lung cancer patients

AACR 2015: Adding a dual mTOR inhibitor to chemo may benefit some ovarian and lung cancer patients

AACR 2015: 'Liquid biopsy' may help earlier detection of lung cancer treatment resistance

AACR 2015: 'Liquid biopsy' may help earlier detection of lung cancer treatment resistance

AACR 2015: Long-term, regular aspirin use modestly decreased cancer risk

AACR 2015: Long-term, regular aspirin use modestly decreased cancer risk

AACR 2015: CART-meso immunotherapy feasible for patients with advanced cancers

AACR 2015: CART-meso immunotherapy feasible for patients with advanced cancers

AACR 2015: Pembrolizumab safe, with signs of clinical benefit, for patients with malignant pleural mesothelioma

AACR 2015: Pembrolizumab safe, with signs of clinical benefit, for patients with malignant pleural mesothelioma

AACR 2015: Pembrolizumab promising for lung cancer, clinical outcomes correlate with biomarker

AACR 2015: Pembrolizumab promising for lung cancer, clinical outcomes correlate with biomarker

DNA blood test detects lung cancer mutations

DNA blood test detects lung cancer mutations

A quarter of advanced lung cancer patients still not tested for EGFR mutations

A quarter of advanced lung cancer patients still not tested for EGFR mutations

Investigational non-small cell lung cancer drug, AZD9291, shows significant delay in disease progression

Investigational non-small cell lung cancer drug, AZD9291, shows significant delay in disease progression

Evidence grows that melanoma drugs benefit some lung cancer patients

Evidence grows that melanoma drugs benefit some lung cancer patients

More from ecancer